Skip to main content
Top
Published in: Endocrine Pathology 4/2018

01-12-2018

TEKT4 Promotes Papillary Thyroid Cancer Cell Proliferation, Colony Formation, and Metastasis through Activating PI3K/Akt Pathway

Authors: Zhouci Zheng, Xiaofen Zhou, Yefeng Cai, Endong Chen, Xiaohua Zhang, Ouchen Wang, Qingxuan Wang, Haiguang Liu

Published in: Endocrine Pathology | Issue 4/2018

Login to get access

Abstract

Thyroid carcinoma is the most common malignancy of the endocrine system worldwide, but its molecular mechanisms remain unclear. Some diseases are associated with TEKT4 gene. However, its role in thyroid carcinoma has yet to be fully examined. This study was designed to investigate the function of TEKT4 in papillary thyroid cancer (PTC). The effect of TEKT4 on aggressive behavior of PTC cell lines, namely, TPC1 and BCPAP, transfected with small interfering RNA was identified through cell proliferation, colony formation, migration, and invasion. Our previous study revealed that TEKT4 may be vital in PTC. In in vitro experiments, TEKT4 downregulation suppressed cell proliferation, colony formation, cell migration, and invasion. Our data also indicated that tumor-suppressing role of TEKT4 knockdown in PTC cell lines was associated with the silence of the PI3K/Akt pathway. Our study revealed that TEKT4 shows important biological implications and is worthy of further study.
Literature
1.
go back to reference Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA: a cancer journal for clinicians. 2015;65(1):5–29. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA: a cancer journal for clinicians. 2015;65(1):5–29.
2.
go back to reference Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ, He J Cancer statistics in China, 2015. CA: a cancer journal for clinicians. 2016;66(2):115–132. Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ, He J Cancer statistics in China, 2015. CA: a cancer journal for clinicians. 2016;66(2):115–132.
3.
go back to reference Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM, Matrisian LM. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer research. 2014;74(11):2913–2921.CrossRef Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM, Matrisian LM. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer research. 2014;74(11):2913–2921.CrossRef
4.
go back to reference Xing M. Molecular pathogenesis and mechanisms of thyroid cancer. Nature reviews Cancer. 2013;13(3):184–199.CrossRef Xing M. Molecular pathogenesis and mechanisms of thyroid cancer. Nature reviews Cancer. 2013;13(3):184–199.CrossRef
5.
go back to reference Xing M. BRAF mutation in thyroid cancer. Endocrine-related cancer. 2005;12(2):245–262.CrossRef Xing M. BRAF mutation in thyroid cancer. Endocrine-related cancer. 2005;12(2):245–262.CrossRef
6.
go back to reference Xing M. Genetic alterations in the phosphatidylinositol-3 kinase/Akt pathway in thyroid cancer. Thyroid : official journal of the American Thyroid Association. 2010;20(7):697–706.CrossRef Xing M. Genetic alterations in the phosphatidylinositol-3 kinase/Akt pathway in thyroid cancer. Thyroid : official journal of the American Thyroid Association. 2010;20(7):697–706.CrossRef
7.
go back to reference Gustafson S, Zbuk KM, Scacheri C, Eng C. Cowden syndrome. Seminars in oncology. 2007;34(5):428–434.CrossRef Gustafson S, Zbuk KM, Scacheri C, Eng C. Cowden syndrome. Seminars in oncology. 2007;34(5):428–434.CrossRef
8.
go back to reference Liu Z, Hou P, Ji M, Guan H, Studeman K, Jensen K, Vasko V, el-Naggar AK, Xing M Highly prevalent genetic alterations in receptor tyrosine kinases and phosphatidylinositol 3-kinase/akt and mitogen-activated protein kinase pathways in anaplastic and follicular thyroid cancers. The Journal of clinical endocrinology and metabolism. 2008;93(8):3106–3116.CrossRef Liu Z, Hou P, Ji M, Guan H, Studeman K, Jensen K, Vasko V, el-Naggar AK, Xing M Highly prevalent genetic alterations in receptor tyrosine kinases and phosphatidylinositol 3-kinase/akt and mitogen-activated protein kinase pathways in anaplastic and follicular thyroid cancers. The Journal of clinical endocrinology and metabolism. 2008;93(8):3106–3116.CrossRef
9.
go back to reference Liu X, Bishop J, Shan Y, Pai S, Liu D, Murugan AK, Sun H, el-Naggar AK, Xing M Highly prevalent TERT promoter mutations in aggressive thyroid cancers. Endocrine-related cancer. 2013;20(4):603–610.CrossRef Liu X, Bishop J, Shan Y, Pai S, Liu D, Murugan AK, Sun H, el-Naggar AK, Xing M Highly prevalent TERT promoter mutations in aggressive thyroid cancers. Endocrine-related cancer. 2013;20(4):603–610.CrossRef
10.
go back to reference Amos LA. The tektin family of microtubule-stabilizing proteins. Genome biology. 2008;9(7):229.CrossRef Amos LA. The tektin family of microtubule-stabilizing proteins. Genome biology. 2008;9(7):229.CrossRef
11.
go back to reference Roy A, Lin YN, Agno JE, DeMayo FJ, Matzuk MM. Absence of tektin 4 causes asthenozoospermia and subfertility in male mice. FASEB journal : official publication of the Federation of American Societies for Experimental Biology. 2007;21(4):1013–1025.CrossRef Roy A, Lin YN, Agno JE, DeMayo FJ, Matzuk MM. Absence of tektin 4 causes asthenozoospermia and subfertility in male mice. FASEB journal : official publication of the Federation of American Societies for Experimental Biology. 2007;21(4):1013–1025.CrossRef
12.
go back to reference Wu WB, Li YS, Ji XF, Wang QX, Gao XM, Yang XF, et al. [Expression of TEKT4 protein decreases in the ejaculated spermatozoa of idiopathic asthenozoospermic men]. Zhonghua nan ke xue = National journal of andrology. 2012;18(6):514–517.PubMed Wu WB, Li YS, Ji XF, Wang QX, Gao XM, Yang XF, et al. [Expression of TEKT4 protein decreases in the ejaculated spermatozoa of idiopathic asthenozoospermic men]. Zhonghua nan ke xue = National journal of andrology. 2012;18(6):514–517.PubMed
13.
go back to reference Jiang YZ, Yu KD, Peng WT, Di GH, Wu J, Liu GY, et al. Enriched variations in TEKT4 and breast cancer resistance to paclitaxel. Nature communications. 2014;5:3802.CrossRef Jiang YZ, Yu KD, Peng WT, Di GH, Wu J, Liu GY, et al. Enriched variations in TEKT4 and breast cancer resistance to paclitaxel. Nature communications. 2014;5:3802.CrossRef
14.
go back to reference Wang QX, Chen ED, Cai YF, Zhou YL, Zheng ZC, Wang YH, Jin YX, Jin WX, Zhang XH, Wang OC Next-generation sequence detects ARAP3 as a novel oncogene in papillary thyroid carcinoma. OncoTargets and therapy. 2016;9:7161–7167.CrossRef Wang QX, Chen ED, Cai YF, Zhou YL, Zheng ZC, Wang YH, Jin YX, Jin WX, Zhang XH, Wang OC Next-generation sequence detects ARAP3 as a novel oncogene in papillary thyroid carcinoma. OncoTargets and therapy. 2016;9:7161–7167.CrossRef
15.
go back to reference Cancer Genome Atlas Research N. Integrated genomic characterization of papillary thyroid carcinoma. Cell. 2014;159(3):676–690.CrossRef Cancer Genome Atlas Research N. Integrated genomic characterization of papillary thyroid carcinoma. Cell. 2014;159(3):676–690.CrossRef
16.
go back to reference Robenshtok E, Nachalon Y, Benbassat C, Hirsch D, Shimon I, Grossman A, Diker-Cohen T, Akirov A, Popovtzer A Disease Severity at Presentation in Patients with Disease-Related Mortality from Differentiated Thyroid Cancer: Implications for the 2015 ATA Guidelines. Thyroid : official journal of the American Thyroid Association. 2017;27(9):1171–1176.CrossRef Robenshtok E, Nachalon Y, Benbassat C, Hirsch D, Shimon I, Grossman A, Diker-Cohen T, Akirov A, Popovtzer A Disease Severity at Presentation in Patients with Disease-Related Mortality from Differentiated Thyroid Cancer: Implications for the 2015 ATA Guidelines. Thyroid : official journal of the American Thyroid Association. 2017;27(9):1171–1176.CrossRef
Metadata
Title
TEKT4 Promotes Papillary Thyroid Cancer Cell Proliferation, Colony Formation, and Metastasis through Activating PI3K/Akt Pathway
Authors
Zhouci Zheng
Xiaofen Zhou
Yefeng Cai
Endong Chen
Xiaohua Zhang
Ouchen Wang
Qingxuan Wang
Haiguang Liu
Publication date
01-12-2018
Publisher
Springer US
Published in
Endocrine Pathology / Issue 4/2018
Print ISSN: 1046-3976
Electronic ISSN: 1559-0097
DOI
https://doi.org/10.1007/s12022-018-9549-0

Other articles of this Issue 4/2018

Endocrine Pathology 4/2018 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.